Novo Nordisk A/S (NVO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Novo Nordisk A/S stock (NVO) is currently trading at $36.33. Novo Nordisk A/S PE ratio is 10.36. Novo Nordisk A/S PS ratio (Price-to-Sales) is 0.53. Analyst consensus price target for NVO is $47.15. WallStSmart rates NVO as Hold.
Novo Nordisk A/S (NVO) stock price prediction for 2030: Base case $1103.49. Bull case $1379.36. Bear case $827.61. See full NVO 2030 price forecast and methodology on WallStSmart.
- NVO PE ratio analysis and historical PE chart
- NVO PS ratio (Price-to-Sales) history and trend
- NVO intrinsic value — DCF, Graham Number, EPV models
- NVO stock price prediction 2025 2026 2027 2028 2029 2030
- NVO fair value vs current price
- NVO insider transactions and insider buying
- Is NVO undervalued or overvalued?
- Novo Nordisk A/S financial analysis — revenue, earnings, cash flow
- NVO Piotroski F-Score and Altman Z-Score
- NVO analyst price target and Smart Rating
Novo Nordisk A/S
📊 No data available
Try selecting a different time range
NVO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Novo Nordisk A/S (NVO)
NVO trades 59% above its Graham fair value of $24.21, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Novo Nordisk A/S (NVO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around peg ratio and price/book. Fundamentals are solid but monitor weak areas for improvement.
Novo Nordisk A/S (NVO) Key Strengths (5)
Every $100 of shareholder equity generates $61 in profit
Keeps $45 of every $100 in revenue after operating costs
Paying less than $1 for every $1 of annual revenue
Keeps $33 of every $100 in revenue as net profit
Large-cap company with substantial market presence
Supporting Valuation Data
Novo Nordisk A/S (NVO) Areas to Watch (5)
Revenue declining -7.60%, a shrinking business
Earnings declining -4.70%, profits shrinking
Very expensive relative to growth, significant premium
Very expensive at 5.5x book value
Very low institutional interest at 9.52%
Supporting Valuation Data
Novo Nordisk A/S (NVO) Detailed Analysis Report
Overall Assessment
This company scores 55/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Price/Sales. Valuation metrics including Price/Sales (0.53) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 60.70%, Operating Margin at 44.50%, Profit Margin at 33.10%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, PEG Ratio. Some valuation metrics including PEG Ratio (4.88), Price/Book (5.45) suggest expensive pricing. Growth concerns include Revenue Growth at -7.60%, EPS Growth at -4.70%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 60.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -7.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Revenue Growth, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NVO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NVO's Price-to-Sales ratio of 0.53x trades at a deep discount to its historical average of 7.24x (1th percentile). The current valuation is 97% below its historical high of 19.61x set in Nov 2007, and 1% above its historical low of 0.53x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Novo Nordisk A/S (NVO) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Novo Nordisk A/S faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 309.1B with 8% decline year-over-year. Profit margins are strong at 33.1%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 6070.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 33.1% and operating margin of 44.5% demonstrate strong pricing power and operational efficiency.
Revenue contracted 8% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -10.8B, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Dividend sustainability with a current yield of 5.0%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Novo Nordisk A/S.
Bottom Line
Novo Nordisk A/S faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Novo Nordisk A/S(NVO)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.